GlassScriptPhysician profile
Sheeba S Thattil
NPI 1932866175
$4,955.62
in general payments reported to CMS, 2019-2025
34 companies · $2,943 in 2025
The $2,943 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.00 · 2022: $223 · 2023: $816 · 2024: $879 · 2025: $2,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,055.25 | 2025 | Rapiblyk |
| Astrazeneca Pharmaceuticals LP | $577.92 | 2021-2025 | Brilinta, Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.17 | 2023-2025 | Jardiance |
| Pfizer INC. | $276.43 | 2023-2025 | |
| Novo Nordisk INC | $273.88 | 2024-2025 | Wegovy |
| Amgen INC. | $219.04 | 2023-2024 | Krystexxa, Repatha |
| Heartflow, INC. | $197.96 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $190.14 | 2023-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $157.27 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $150.23 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $141.94 | 2025 | Amvuttra |
| Abbvie INC. | $124.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $122.67 | 2024 | Ultomiris |
| Dynavax Technologies Corporation | $108.93 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $108.02 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $103.48 | 2025 | Prolastin-C Liquid |
| Fresenius Kabi USA, LLC | $90.72 | 2024 | Smoflipid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.72 | 2025 | Xifaxan |
| Philips North America LLC | $68.97 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.67 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $57.29 | 2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Esperion Therapeutics, INC. | $53.99 | 2025 | Nexletol |
| Ars Pharmaceuticals Operations, INC. | $50.00 | 2025 | Neffy |
| Smith+Nephew, INC. | $47.11 | 2025 | Collagenase Santyl |
| Lexicon Pharmaceuticals, INC. | $45.98 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $45.32 | 2025 | Opsynvi, Uptravi |
| Biosense Webster, INC. | $44.19 | 2025 | Carto 3 |
| Madrigal Pharmaceuticals | $40.28 | 2025 | Rezdiffra |
| Medicomp INC | $37.29 | 2024-2025 | Telepatch Cardiac Monitor |
| Merck Sharp & Dohme LLC | $28.86 | 2023 | Verquvo |
| Watermark Medical, INC. | $27.49 | 2024 | |
| Janssen Pharmaceuticals, INC | $24.11 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $20.41 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $19.79 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheeba Thattil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.